503B facilities play a key role in healthcare around the US. More than providing medications, they empower hospitals to maintain excellence during unforeseen demands. That’s why, when a 503B facility exits the market, it can leave a gap that echoes through the halls of a hospital, down to the patients in every room.
Many 503B facilities are established to fill short-term medication shortages. However, the brief duration of these shortages, stringent Current Good Manufacturing Practice (cGMP) standards, shorter beyond-use dates (BUDs), strict FDA inspections, and the expense of maintaining quality facilities mean that many 503Bs do not sustain long-term business models.
They make short-term profits by meeting short-term needs, and then they exit the market. Each time that happens, hospitals and patients can pay unseen costs.
Unseen Costs of Exits
Procurement teams and other staff in hospital pharmacies must perform a complicated balancing act to plan and purchase the medications that will meet future needs, without the wasted expense of excess stock that expires.
These teams know their facility and its service area, but external factors can force pharmacies into a firefighting mode where they must struggle to quickly adapt. This growing volatility adds a layer of uncertainty, stress, and expense to everyday operations.
Uncertainty, and the difficulty of meeting today’s regulatory compounding standards, have meant that hospitals increasingly rely on 503Bs. But, when hospitals simply seek the lowest cost on each medication, they can form a fragmented network of 503Bs that only exist to meet short-term needs.
When those 503Bs leave the market, hospitals can struggle with new vendors and unseen costs:
-
- New vendor vetting: Not all 503B facilities are the same. Healthcare providers need to conduct continuous due diligence that analyzes a facility’s FDA inspection history, Form 483s, and recall records before establishing a contract. Even when services are outsourced, the prescribing and dispensing providers remain legally liable for the quality, purity, and administration of the compounded drugs. So, every new and unproven vendor can introduce new risks.
-
- Supply chain volatility: As hospitals seek to replace exited 503Bs, they risk choosing other 503B facilities that have tied their production pipelines to short-term drug shortages. As soon as a commercial shortage ends and mass-manufactured supply returns, these short-term suppliers lose their competitive edge and pull the product from their catalog, leaving hospitals in the same situation without a steady source of medications.
-
- Inflexible contracts: When hospitals replace former 503Bs with new vendors, they can be required to establish ongoing orders that require them to purchase regular allotments even if their needs change. Without any flexibility to adapt these orders, hospitals can quickly accrue waste costs and medications that they know they will not be able to use.
-
- Lack of transparency: There is no universal, centralized database for all products compounded by 503B facilities. Many 503Bs offer little transparency into their processes, and limited reporting about medication status and availability. Clinicians must contact each outsourced compounding facility individually to check inventory. Plus, 503Bs use varying naming conventions for the same products, creating data entry and tracking challenges for health record systems and clinical decision support.
These issues might lead hospitals to consider insourcing the majority of their compounding needs. However, the significant cost of establishing and maintaining compliance with complex USP <797> and USP <800> standards, with shorter beyond-use dates than 503Bs, means that compounding everything is impractical even for many large healthcare providers.
The best option for cost, quality and consistent patient care is often a long-term 503B partner.
Savings of a Long-term 503B Partner
A long-term 503B partner can help hospitals reduce medication supply instability and waste, while alleviating the lingering workforce stress of uncertain supplies.
The stability of a steady 503B partner can yield savings in many ways:
-
- Ongoing quality assurance: An ongoing relationship centralizes the healthcare provider’s compliance footprint. Pharmacy teams only need to evaluate and maintain relationships with one outsourcing facility. This establishes a transparent, open-door relationship that lowers the administrative burden on quality assurance staff.
-
- Supply chain stability: A dedicated 503B partner offers proactive shortage forecasting and allocation priority. During national shortages, a primary provider can prioritize committed partners over opportunistic buyers, ensuring a more predictable supply for critical medications and a continuation of consistent patient care.
-
- Flexible supply: A strategic 503B partner aligns its manufacturing schedules with client utilization data, offering extended BUDs backed by robust stability studies that are tailored to the healthcare provider’s needs, smoother logistics, and predictable delivery windows to help minimize waste. An ongoing relationship turns the 503B provider into an extension of the hospital’s own pharmacy, even offering a variety of concentrations and doses that meet healthcare facility needs.
-
- Transparency and label clarity: A long-term partner allows for standardization, with consistent labeling and predictable barcodes that seamlessly integrate with a provider’s Electronic Health Record (EHR) and BCMA (Barcode Medication Administration) systems and uniform concentrations. This drastically reduces cognitive load for nursing and anesthesia staff, reducing the risk of lookalike and soundalike medication errors.
A strategy that spreads demand across multiple 503B vendors might seem like a good way to mitigate the risk of short-term shortages, but it can actually introduce a range of other risks every day.
One of the greatest risks is that a vetted vendor could exit the market entirely.
The more that a healthcare provider can collaborate closely with dedicated 503B partners, the more it can evolve from transaction-based volatility to an ongoing operational partnership.
The Price for Patients
When a 503B facility exits, the price can be paid in uncertainty around the patient care in every hospital room.
Patient care requires an ongoing commitment to all of the myriad factors and decisions that happen at every level, from visionary institutional strategies to clear labels on every medication. Hospitals that prioritize patient care understand that they must foster consistent and effective support for excellence at every level.
When hospitals prioritize risk reduction, reliable supply, and long-term cost management, they establish long-term relationships that ultimately build a foundation for more consistent and excellent care.
